1. Home
  2. Live Updates
  3. Servier

Live Breaking News & Updates on Servier

Stay informed with the latest breaking news from Servier on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Servier and stay connected to the pulse of your community

Mokoro elected chair of pharmaceutical association Kapi

He was elected during Kapi's 19th AGM

Dawa , Coast , Kenya , David-odhiambo-novartis , Christopher-odero-roche , Stella-kiptanui , Winnie-nganga , James-mokoro , John-mwangi-bayer , Michael-onyango-medsource , Mac-naughton-pharma , Limitde-aspen

Why Failing Faster Is the Key to Accelerating Drug Discovery

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Dale-porter , Robertf-kennedy , Deloitte-centre-for-health-solutions , Institute-for-human-data-science , Deloitte , Innovation-engine , Harnessing-external , Lessons-that-ultimately-lead , Human-data , Global-trends , Digital-momentum , Return-from-pharmaceutical-innovation

FDA Grants Priority Review to Ivosidenib for IDH1+ Relapsed/Refractory MDS

The FDA has granted priority review to the supplemental new drug application seeking the approval of ivosidenib for the treatment of patients with IDH1-mutated, relapsed/refractory myelodysplastic syndrome.

Germany , Susan-pandya , European-hematology-association-congress , European-hematology-association , Cancer-metabolism-global-development-oncology-immuno , York-heart-association , Cancer-metabolism-global-development-oncology , New-york-heart-association , Hematology-association , Hematology-association-congress , Ivosidenib- , Patients-with-idh1-mutated

Form 10-Q XOMA Corp For: Jun 30

Form 10-Q XOMA Corp For: Jun 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , California , San-francisco-bay , Delaware , Ukraine , Emeryville , Washington , American , America , Owen-hughes , Chiesi-farmaceutici , Jamesr-neal

Form 10-Q XOMA Corp For: Mar 31

Form 10-Q XOMA Corp For: Mar 31
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Delaware , San-francisco-bay , California , Ukraine , Washington , Emeryville , American , America , Incyte-europe , Bradley-sitko , Chiesi-farmaceutici

Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in EuropeThe positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA)

Norway , Iceland , Liechtenstein , Paris , France-general- , France , Dennis-riedl , Prnewswire-servier , Claude-bertrand , European-union , European-medicines-agency , European-commission

Servier full year 2021/22 results confirm the transformation trajectory of the Group

Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales Sales revenue for brand-name medicines...

United-states , Paris , France-general- , France , Prnewswire-servier , Olivier-laureau , International-financial-reporting-standards , Servier ,

Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium

Patients treated with the investigational combination of trifluridine/tipiracil in combination with bevacizumab in the pivotal Phase 3 SUNLIGHT trial achieved clinically meaningful improvement in

Oakville , Ontario , Canada , United-states , Nigeria , New-jersey , Brazil , Switzerland , France , San-francisco , California , Canadian

Servier unveils its 2030 ambition and reveals a new visual identity

/PRNewswire/ -- Servier today unveils its 2030 ambition as well as a new visual identity that reflects the transformation undertaken by the Group, bringing...

Saclay , France-general- , France , Japan , Nigeria , United-states , Hungary , Paris , Brazil , Prnewswire-servier , Olivier-laureau , Servier-research

Servier Exercises the Exclusive Worldwide License Option of Their Collaboration Program With Oncodesign Precision Medicine (OPM) on Parkinson's disease

CTA1 approval by the ANSM2 and the EC3 of the phase 1 program resulting from the collaboration between Servier and Oncodesign Precision Medicine for the development of an innovative treatment in Parkinson's

Paris , France-general- , France , French , Ross-jeggo , Arthur-rouill , Mathilde-bohin , Philippe-genne , Sonia-marques , Jan-hoflack , Instagram , Linkedin